Close Menu

NEW YORK (GenomeWeb) – Predicine announced today that it has closed a $13.5 million Series A round of financing.

Chinese venture capital firms Sangel Capital, Rongsheng Investment, and Highlight Capital participated in the round.

Predicine said it will use the funding to advance the commercialization of its proprietary liquid biopsy technology, as well as its use in clinical trials, treatment selection, and cancer screening. The firm also intends to expand its cancer biomarker pipeline.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.